ARPA-H Launches ADVOCATE to Bring Agentic AI to Heart Disease Care
March 23, 2026 · 2 min read
Arthur Griffin
The Advanced Research Projects Agency for Health has launched ADVOCATE — the Agentic AI-Enabled Cardiovascular Care Transformation program — an ambitious effort to develop the first FDA-authorized agentic AI system capable of providing round-the-clock specialty cardiology care to the millions of Americans who lack access to a cardiologist.
Full proposals are due April 1, 2026 at 5:00 PM ET.
Nearly Half of U.S. Counties Have No Cardiologist
Heart disease remains the leading cause of death in the United States, yet 46 percent of U.S. counties lack a single cardiologist. ARPA-H envisions ADVOCATE closing that gap by creating AI agents that function as clinician extenders — providing patients with 24/7 access to personalized dietary guidance, exercise recommendations, care navigation, appointment scheduling, and diagnostic assessments with treatment plans.
The technology goes further than any existing health AI: ADVOCATE systems must be capable of writing or modifying in-scope prescriptions autonomously, under the supervision of a separate AI safety agent that monitors clinical consistency and effectiveness in real time.
Three Technical Tracks, One 39-Month Timeline
ARPA-H has structured ADVOCATE around three technical areas: a patient-facing clinical AI agent, a supervisory agent ensuring safety and clinical standards, and a scalable integration plan for deployment in real-world healthcare systems. The entire project, including FDA authorization, is designed to complete within 39 months.
Teams selected for funding will be announced in June 2026. ARPA-H used a two-phase evaluation process: solution summaries were due February 27, and full proposals close April 1. The agency has published a statement on its use of AI tools in the proposal review process.
What Health Tech Innovators Should Know
ADVOCATE represents a paradigm shift in how the federal government approaches health AI — moving from advisory tools to autonomous clinical agents with prescribing authority. Teams with expertise in clinical AI, cardiology, FDA regulatory pathways, and healthcare system integration are best positioned to compete.
The program's aggressive timeline and FDA authorization requirement mean ARPA-H will favor teams with existing clinical partnerships and regulatory experience over purely academic proposals. Organizations tracking federal health innovation funding can find ongoing analysis at grantedai.com.